Identification

Name
Sulindac
Accession Number
DB00605  (APRD01243)
Type
Small Molecule
Groups
Approved, Investigational
Description

Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril. Like other NSAIAs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver enzymes. The sulfide metabolite then undergoes enterohepatic circulation; it is excreted in the bile and then reabsorbed from the intestine. This is thought to help maintain constant blood levels with reduced gastrointestinal side effects. Some studies have shown sulindac to be relatively less irritating to the stomach than other NSAIA's except for drugs of the cyclooxygenase-2 (COX-2) inhibitor class. The exact mechanism of its NSAIA properties is unknown, but it is thought to act on enzymes COX-1 and COX-2, inhibiting prostaglandin synthesis.

Structure
Thumb
Synonyms
  • (Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
  • cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
  • cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
  • Sulindac
  • Sulindaco
  • Sulindacum
Product Ingredients
IngredientUNIICASInChI Key
Sulindac sodiumNJV14I2XPC63804-15-9YMXUJDLCLXHYBO-WPTDRQDKSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clinoril Tab 150mgTablet150 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1979-12-311998-08-14Canada
Clinoril Tab 200mgTablet200 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1979-12-311998-08-14Canada
Sulindac-150 Tab 150mgTablet150 mgOralPro Doc Limitee1989-12-312009-07-23Canada
Sulindac-200 Tab 200mgTablet200 mgOralPro Doc Limitee1989-12-312009-07-23Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sulin Tab 150mgTablet150 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-sulin Tab 200mgTablet200 mgOralApotex Corporation1988-12-31Not applicableCanada
Nu-sulindac Tab 150mgTablet150 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Nu-sulindac Tab 200mgTablet200 mgOralNu Pharm Inc1994-12-312012-09-04Canada
Penta-sulindacTablet150 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-sulindacTablet200 mgOralPentapharm Ltd.Not applicableNot applicableCanada
SulindacTablet150 mg/1OralPura Cap Laboratories Llc Dba Blu Pharmaceuticals2016-11-14Not applicableUs
SulindacTablet150 mg/1OralEpic Pharma, LLC2015-07-282017-12-22Us
SulindacTablet200 mg/1OralActavis Pharma Company1990-04-03Not applicableUs
SulindacTablet150 mg/1OralSun Pharmaceutical Industries Limited2009-09-04Not applicableUs
International/Other Brands
Clinoril (Merck)
Categories
UNII
184SNS8VUH
CAS number
38194-50-2
Weight
Average: 356.411
Monoisotopic: 356.088243305
Chemical Formula
C20H17FO3S
InChI Key
MLKXDPUZXIRXEP-MFOYZWKCSA-N
InChI
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
IUPAC Name
2-[(1Z)-5-fluoro-1-[(4-methanesulfinylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid
SMILES
CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(C=C1)S(C)=O

Pharmacology

Indication

For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.

Associated Conditions
Pharmacodynamics

Sulindac is a non-steroidal anti-inflammatory indene derivative, also possessing analgesic and antipyretic activities.

Mechanism of action

Sulindac's exact mechanism of action is unknown. Its antiinflammatory effects are believed to be due to inhibition of both COX-1 and COX-2 which leads to the inhibition of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
UAldose reductase
inhibitor
Human
UMitogen-activated protein kinase 3
inhibitor
Human
UPeroxisome proliferator-activated receptor delta
negative modulator
Human
UProstaglandin D2 receptor 2
antagonist
Human
UAldo-keto reductase family 1 member B10
inhibitor
Human
Absorption

Approximately 90% absorbed in humans following oral administration.

Volume of distribution
Not Available
Protein binding

At 1 mcg/ml concentrations, approximately 93% sulindac and 98% of its sulfide metabolite are bound to human serum albumin.

Metabolism

Undergoes two major biotransformations: reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Sulindac and its sulfide and sulfone metabolites undergo extensive enterohepatic circulation. Available evidence indicates that the biological activity resides with the sulfide metabolite. Side chain hydroxylation and hydration of the double bond also occur.

Route of elimination

Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk. Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Hepatic metabolism is an important elimination pathway.

Half life

The mean half-life of sulindac is 7.8 hours while the mean half-life of the sulfide metabolite is 16.4 hours.

Clearance
  • Renal cl=68.12 +/- 27.56 mL/min [NORMAL (19-41 yrs)]
Toxicity

Acute oral toxicity (LD50) in rats is 264 mg/kg. Cases of overdose have been reported and rarely, deaths have occurred. The following signs and symptoms may be observed following overdose: stupor, coma, diminished urine output and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Sulindac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinSulindac may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinSulindac may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinSulindac may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Abciximab.Approved
AcebutololSulindac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Sulindac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSulindac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Sulindac.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Acetylsalicylic acid.Approved, Vet Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Sulindac.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of gastrointestinal irritation can be increased when Alclometasone is combined with Sulindac.Approved
AldosteroneThe risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Sulindac.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Alendronic acid.Approved
AliskirenThe risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Alminoprofen.Experimental
AloxiprinThe therapeutic efficacy of Aloxiprin can be decreased when used in combination with Sulindac.Experimental
AlprenololSulindac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Sulindac.Approved, Investigational
AlteplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Sulindac.Approved, Investigational
AmcinonideThe risk or severity of gastrointestinal irritation can be increased when Amcinonide is combined with Sulindac.Approved
AmediplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Amediplase.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe therapeutic efficacy of Aminosalicylic Acid can be decreased when used in combination with Sulindac.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Sulindac.Approved
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Sulindac.Approved, Investigational
AnagrelideThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ancrod.Approved, Investigational
AnisodamineSulindac may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Sulindac is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Sulindac is combined with Antrafenine.Approved
ApixabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Argatroban.Approved, Investigational
ArotinololSulindac may decrease the antihypertensive activities of Arotinolol.Investigational
AstaxanthinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Astaxanthin.Investigational
AtenololSulindac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Sulindac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Sulindac.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Sulindac is combined with Balsalazide.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Sulindac.Approved, Investigational
BefunololSulindac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulindac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Sulindac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Sulindac is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Sulindac.Approved, Withdrawn
BeraprostThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Beraprost.Investigational
BesifloxacinSulindac may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Sulindac.Approved, Vet Approved
BetaxololSulindac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Sulindac.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Sulindac.Approved, Investigational
BevantololSulindac may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Sulindac.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulindac.Approved, Investigational
BisoprololSulindac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Bivalirudin.Approved, Investigational
BopindololSulindac may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Sulindac.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Sulindac.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Sulindac.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Sulindac.Approved
BrinaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Sulindac.Approved
BucindololSulindac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Sulindac.Approved
BufexamacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bufexamac.Approved, Experimental
BufuralolSulindac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Sulindac.Approved
BupranololSulindac may decrease the antihypertensive activities of Bupranolol.Approved
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Sulindac.Experimental
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Sulindac.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Sulindac.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Sulindac.Experimental
CangrelorThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Cangrelor.Approved
CapreomycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sulindac is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulindac.Approved
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Sulindac.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololSulindac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSulindac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CefacetrileThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Sulindac.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Sulindac.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Sulindac.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Sulindac.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Sulindac.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Sulindac.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Sulindac.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Sulindac.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Sulindac.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Sulindac.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Sulindac.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Sulindac.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Sulindac.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Sulindac.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulindac.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Sulindac.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Sulindac.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Sulindac.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Sulindac.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Sulindac.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Sulindac.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Sulindac.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Sulindac.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Sulindac.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Sulindac.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Sulindac.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Sulindac.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Sulindac.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Sulindac.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sulindac.Approved, Investigational
CeliprololSulindac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cephalothin Group.Experimental
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Certoparin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Sulindac.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulindac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Sulindac.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Sulindac.Investigational
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Cimicoxib.Investigational
CinoxacinSulindac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinSulindac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Sulindac.Approved
CitalopramCitalopram may increase the antiplatelet activities of Sulindac.Approved
ClobetasolThe risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Sulindac.Approved, Investigational
Clobetasol propionateThe risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Sulindac.Approved
ClobetasoneThe risk or severity of gastrointestinal irritation can be increased when Clobetasone is combined with Sulindac.Approved
ClocortoloneThe risk or severity of gastrointestinal irritation can be increased when Clocortolone is combined with Sulindac.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Sulindac.Approved
ClonixinThe risk or severity of adverse effects can be increased when Sulindac is combined with Clonixin.Approved
CloprednolThe risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Sulindac.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Sulindac.Vet Approved
CloranololSulindac may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneSulindac may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Sulindac.Approved, Vet Approved
CorticotropinThe risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Sulindac.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Sulindac.Approved, Investigational
CortivazolThe risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Sulindac.Investigational
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Sulindac.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sulindac.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Sulindac.Approved
Dabigatran etexilateThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dabigatran etexilate.Approved
DalteparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Sulindac.Investigational
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Darexaban.Investigational
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Sulindac.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Sulindac is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Sulindac.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Delapril.Investigational
DersalazineThe therapeutic efficacy of Dersalazine can be decreased when used in combination with Sulindac.Investigational
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Sulindac.Approved
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Desirudin.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Sulindac is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Desmoteplase.Investigational
DesonideThe risk or severity of gastrointestinal irritation can be increased when Desonide is combined with Sulindac.Approved, Investigational
DesoximetasoneThe risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Sulindac.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Sulindac.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Sulindac.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Sulindac.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Sulindac.Experimental
DextranThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Sulindac.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulindac.Approved, Vet Approved
DicoumarolSulindac may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Sulindac.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Sulindac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of gastrointestinal irritation can be increased when Diflorasone is combined with Sulindac.Approved
DifloxacinSulindac may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Sulindac.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of gastrointestinal irritation can be increased when Difluprednate is combined with Sulindac.Approved
DigoxinSulindac may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Sulindac.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Sulindac.Approved, Investigational
Dimethyl sulfoxideThe metabolism of Sulindac can be decreased when combined with Dimethyl sulfoxide.Approved, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Sulindac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulindac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Sulindac.Approved
DiphenadioneSulindac may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dipyridamole.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ditazole.Approved, Withdrawn
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Sulindac.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Sulindac.Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Sulindac is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Sulindac.Approved
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Sulindac.Approved, Investigational
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Sulindac.Experimental
EnoxacinSulindac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Sulindac.Experimental
EpanololSulindac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Sulindac is combined with Epirizole.Approved
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulindac.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Sulindac.Approved
EsatenololSulindac may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Sulindac.Approved, Investigational
EsmololSulindac may decrease the antihypertensive activities of Esmolol.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulindac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Sulindac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSulindac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Sulindac is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Etoricoxib.Approved, Investigational
FelbinacThe risk or severity of adverse effects can be increased when Sulindac is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sulindac.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Sulindac is combined with Fenbufen.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Sulindac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Sulindac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Sulindac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Sulindac.Experimental
FibrinolysinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Sulindac.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Firocoxib.Experimental, Vet Approved
FleroxacinSulindac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Sulindac is combined with Floctafenine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Sulindac.Investigational
FlucloroloneThe risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Sulindac.Experimental
FludrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Sulindac.Approved, Investigational
FluindioneSulindac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSulindac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Sulindac.Approved, Vet Approved
FlunisolideThe risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Sulindac.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Sulindac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinolone Acetonide is combined with Sulindac.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Sulindac.Approved, Investigational
FluocortinThe risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Sulindac.Experimental
FluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Sulindac.Approved, Withdrawn
FluorometholoneThe risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Sulindac.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Sulindac.Approved, Vet Approved
FluperoloneThe risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Sulindac.Experimental
FluprednideneThe risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Sulindac.Approved, Withdrawn
FluprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Sulindac.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Sulindac.Vet Approved
FlurandrenolideThe risk or severity of gastrointestinal irritation can be increased when Flurandrenolide is combined with Sulindac.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Sulindac.Approved, Investigational
FluticasoneThe risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Sulindac.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Sulindac.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Sulindac.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Sulindac.Approved, Investigational
FondaparinuxThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Sulindac.Experimental
FormocortalThe risk or severity of gastrointestinal irritation can be increased when Formocortal is combined with Sulindac.Experimental
FoscarnetThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Fosinoprilat.Experimental
FramycetinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Sulindac.Approved, Vet Approved
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Gabexate.Investigational
GarenoxacinSulindac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSulindac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Sulindac.Approved, Withdrawn
GemifloxacinSulindac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with GENTAMICIN C1A.Experimental
GliclazideThe protein binding of Gliclazide can be decreased when combined with Sulindac.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Sulindac.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Sulindac.Approved
GrepafloxacinSulindac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Sulindac is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Sulindac.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Sulindac.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Sulindac.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Sulindac.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Sulindac.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Sulindac.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Sulindac.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Sulindac.Experimental
HalcinonideThe risk or severity of gastrointestinal irritation can be increased when Halcinonide is combined with Sulindac.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of gastrointestinal irritation can be increased when Halometasone is combined with Sulindac.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Sulindac.Approved
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Sulindac.Experimental
HydralazineSulindac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Sulindac.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone aceponate is combined with Sulindac.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Sulindac.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Sulindac.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone probutate is combined with Sulindac.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Sulindac.Approved
Hydrocortisone valerateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone valerate is combined with Sulindac.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulindac.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Hydrolyzed Cephalothin.Experimental
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Sulindac is combined with Icosapent.Approved, Nutraceutical
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Idraparinux.Investigational
IloprostThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Imidazole salicylate.Experimental
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Incadronic acid.Approved, Investigational
IndalpineIndalpine may increase the antiplatelet activities of Sulindac.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.Approved
IndenololSulindac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Sulindac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Indoprofen.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Sulindac.Withdrawn
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Sulindac.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Sulindac.Approved, Investigational
KanamycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Kebuzone.Experimental
KetanserinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Sulindac.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulindac.Approved
LabetalolSulindac may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sulindac.Approved, Investigational
LandiololSulindac may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Sulindac.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulindac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Sulindac.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Sulindac.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Letaxaban.Investigational
LevobetaxololSulindac may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololSulindac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSulindac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Sulindac.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Sulindac.Approved, Investigational
LinsidomineThe therapeutic efficacy of Linsidomine can be decreased when used in combination with Sulindac.Experimental
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Lisinopril.Approved, Investigational
Lithium cationSulindac may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Sulindac.Approved, Investigational
LomefloxacinSulindac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lonazolac.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Sulindac.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Sulindac.Approved
LoteprednolThe risk or severity of gastrointestinal irritation can be increased when Loteprednol is combined with Sulindac.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Sulindac.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Sulindac.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Sulindac.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Sulindac.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Sulindac.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of gastrointestinal irritation can be increased when Medrysone is combined with Sulindac.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Mefenamic acid.Approved
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Melagatran.Experimental
MelengestrolThe risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Sulindac.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.Approved, Vet Approved
MepindololSulindac may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Sulindac.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Sulindac is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Sulindac is combined with Metamizole.Approved, Investigational, Withdrawn
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Sulindac.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sulindac.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Sulindac.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Sulindac.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Sulindac.Approved, Vet Approved
MetipranololSulindac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac.Approved
MetoprololSulindac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Sulindac.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Sulindac.Investigational, Withdrawn
MicronomicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Micronomicin.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Sulindac.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Sulindac.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Sulindac.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulindac.Approved
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Sulindac.Approved, Vet Approved
Mometasone furoateThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Sulindac.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Sulindac is combined with Morniflumate.Approved
MoxifloxacinSulindac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Sulindac.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Sulindac.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Sulindac.Approved
NadololSulindac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Nafamostat.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Sulindac.Investigational
Nalidixic AcidSulindac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Sulindac is combined with Naproxen.Approved, Vet Approved
NeamineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Neamine.Experimental
NebivololSulindac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Sulindac.Approved, Withdrawn
NemonoxacinSulindac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Sulindac.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Netilmicin.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Sulindac.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Sulindac.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Sulindac is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Sulindac.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Sulindac.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Sulindac.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sulindac.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulindac.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Sulindac is combined with Nitroaspirin.Investigational
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Sulindac.Approved, Investigational
NorfloxacinSulindac may increase the neuroexcitatory activities of Norfloxacin.Approved
NS-398The risk or severity of adverse effects can be increased when Sulindac is combined with NS-398.Experimental
OfloxacinSulindac may increase the neuroexcitatory activities of Ofloxacin.Approved
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Sulindac.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Sulindac is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Sulindac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Omapatrilat.Investigational
OrbifloxacinSulindac may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.Approved
Oxolinic acidSulindac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSulindac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Sulindac.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Parecoxib.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Sulindac.Approved
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Sulindac.Approved, Investigational
PazufloxacinSulindac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSulindac may increase the neuroexcitatory activities of Pefloxacin.Approved
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Sulindac.Approved, Investigational
PenbutololSulindac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Pentamidine.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Sulindac.Approved
Pentosan PolysulfateThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Perindoprilat.Experimental
PhenindioneSulindac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Sulindac.Approved
PhenprocoumonSulindac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Sulindac.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Sulindac.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Phenylbutazone.Approved, Vet Approved
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Sulindac.Approved
PindololSulindac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidSulindac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Sulindac.Approved
Piromidic acidSulindac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Sulindac is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Plazomicin.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulindac.Approved
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololSulindac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateSulindac may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Prasugrel.Approved
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Sulindac.Approved
PrednicarbateThe risk or severity of gastrointestinal irritation can be increased when Prednicarbate is combined with Sulindac.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Sulindac.Approved, Vet Approved
PrednisoneThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Sulindac.Approved, Vet Approved
PrednylideneThe risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Sulindac.Experimental
ProbenecidProbenecid may decrease the excretion rate of Sulindac which could result in a higher serum level.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Sulindac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Sulindac is combined with Propacetamol.Approved, Investigational
PropafenoneSulindac may decrease the antihypertensive activities of Propafenone.Approved
PropranololSulindac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Sulindac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Sulindac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Sulindac.Vet Approved
Protein CThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Protocatechualdehyde.Approved
PrulifloxacinSulindac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Puromycin.Experimental
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Quinaprilat.Experimental
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Ramiprilat.Experimental
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Sulindac.Approved
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Sulindac.Approved, Investigational
ReteplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Ribostamycin.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Sulindac.Approved, Investigational
RimexoloneThe risk or severity of gastrointestinal irritation can be increased when Rimexolone is combined with Sulindac.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Sulindac.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Risedronate.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Sulindac.Investigational
RivaroxabanThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Rivaroxaban.Approved
RobenacoxibThe risk or severity of adverse effects can be increased when Sulindac is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Sulindac.Approved, Investigational, Withdrawn
RosoxacinSulindac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSulindac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Sulindac is combined with Salsalate.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Sulindac.Experimental
SarafloxacinSulindac may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Sulindac.Investigational
SaruplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Saruplase.Experimental
SC-236The risk or severity of adverse effects can be increased when Sulindac is combined with SC-236.Experimental, Investigational
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Sulindac.Approved
SertralineSertraline may increase the antiplatelet activities of Sulindac.Approved
SibutramineSibutramine may increase the antiplatelet activities of Sulindac.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Sisomicin.Investigational
SitafloxacinSulindac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Sulindac.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Sulindac.Approved
SotalolSulindac may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinSulindac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Streptomycin.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulindac is combined with Sulfasalazine.Approved
SulodexideThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Sulindac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Sulindac is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of renal failure can be increased when Sulindac is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Sulindac.Approved
TalinololSulindac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Sulindac is combined with Talniflumate.Approved
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Sulindac.Approved
Technetium Tc-99m ciprofloxacinSulindac may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Sulindac.Approved, Investigational
TemafloxacinSulindac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Sulindac is combined with Tenidap.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Sulindac.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulindac.Approved
Tenofovir disoproxilSulindac may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Sulindac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Sulindac is combined with Tepoxalin.Vet Approved
TerazosinThe therapeutic efficacy of Terazosin can be decreased when used in combination with Sulindac.Approved
TertatololSulindac may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Sulindac.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Sulindac is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ticagrelor.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Sulindac.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSulindac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Sulindac is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Tinzaparin.Approved
TioclomarolSulindac may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Sulindac.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Tobramycin.Approved, Investigational
TocopherylquinoneThe therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Sulindac.Experimental, Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Sulindac.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Sulindac.Approved, Vet Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Sulindac.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Sulindac is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulindac.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Sulindac.Experimental
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Sulindac.Approved
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulindac.Approved
TrazodoneTrazodone may increase the antiplatelet activities of Sulindac.Approved, Investigational
TreprostinilThe risk or severity of bleeding can be increased when Treprostinil is combined with Sulindac.Approved, Investigational
TriamcinoloneThe risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Sulindac.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulindac.Approved, Vet Approved
TriflusalThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Sulindac.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Sulindac.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Sulindac.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Sulindac is combined with Trolamine salicylate.Approved
TrovafloxacinSulindac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Troxerutin.Investigational
UlobetasolThe risk or severity of gastrointestinal irritation can be increased when Ulobetasol is combined with Sulindac.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulindac.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Sulindac.Investigational
UrokinaseThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Sulindac.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Sulindac.Approved, Investigational
VancomycinSulindac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Sulindac.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Sulindac.Experimental
VorapaxarThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Vorapaxar.Approved
WarfarinSulindac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Sulindac.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Sulindac is combined with Zaltoprofen.Approved, Investigational
ZimelidineZimelidine may increase the antiplatelet activities of Sulindac.Withdrawn
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Sulindac is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Gary Piazza, Robert Reynolds, "Derivatives of sulindac, use thereof and preparation thereof." U.S. Patent US20070244122, issued October 18, 2007.

US20070244122
General References
Not Available
External Links
Human Metabolome Database
HMDB0014743
KEGG Drug
D00120
KEGG Compound
C01531
PubChem Compound
1548887
PubChem Substance
46506570
ChemSpider
1265915
BindingDB
50012899
ChEBI
9352
ChEMBL
CHEMBL15770
Therapeutic Targets Database
DAP000569
PharmGKB
PA451565
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sulindac
ATC Codes
M01AB02 — Sulindac
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (106 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionCancer, Breast1
2Active Not RecruitingTreatmentDesmoid Tumors1
2CompletedPreventionAdenomatous Polyposis Coli1
2CompletedPreventionMalignant Neoplasm of Colon / Precancerous Conditions / Rectal Carcinoma1
2CompletedPreventionPrecancerous Conditions1
2CompletedPreventionPrecancerous Conditions / Stage I Non-Small Cell Lung Cancer / Tobacco Use Disorders1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingPreventionCancers / High Blood Pressure (Hypertension) / Inflammatory Reaction / Pain1
2TerminatedPreventionColorectal Cancers1
2TerminatedTreatmentColorectal Adenocarcinoma / Colorectal Cancers / Liver Metastasis1
2Unknown StatusPreventionAdenomatous Polyposis Coli1
2WithdrawnDiagnosticFocus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms1
2WithdrawnTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
3CompletedPreventionPrecancerous Conditions1
Not AvailableActive Not RecruitingTreatmentNeoplasms, Benign / Oral Leukoplakia1
Not AvailableCompletedPreventionUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedPreventionAberrant Crypt Foci1
Not AvailableTerminatedPreventionColorectal Cancers1

Pharmacoeconomics

Manufacturers
  • Merck research laboratories div merck co inc
  • Epic pharma llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
  • A-S Medication Solutions LLC
  • Avkare Incorporated
  • Bryant Ranch Prepack
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Endo Pharmaceuticals Inc.
  • Epic Pharma LLC
  • Golden State Medical Supply Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Heritage Pharmaceuticals
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Richmond Pharmacy
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral150 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Sulindac powder17.36USD g
Clinoril 200 mg tablet1.58USD tablet
Sulindac 200 mg tablet1.23USD tablet
Sulindac 150 mg tablet1.0USD tablet
Apo-Sulin 200 mg Tablet0.51USD tablet
Novo-Sundac 200 mg Tablet0.51USD tablet
Nu-Sulindac 200 mg Tablet0.51USD tablet
Apo-Sulin 150 mg Tablet0.4USD tablet
Novo-Sundac 150 mg Tablet0.4USD tablet
Nu-Sulindac 150 mg Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)183 °CPhysProp
water solubility3000 mg/LMERCK INDEX (1996); pH 7
logP3.42SANGSTER (1993)
pKa4.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0251 mg/mLALOGPS
logP2.96ALOGPS
logP2.93ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.09ChemAxon
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.56 m3·mol-1ChemAxon
Polarizability37.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.8325
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5904
P-glycoprotein inhibitor INon-inhibitor0.5847
P-glycoprotein inhibitor IINon-inhibitor0.9949
Renal organic cation transporterNon-inhibitor0.8753
CYP450 2C9 substrateNon-substrate0.7715
CYP450 2D6 substrateNon-substrate0.8961
CYP450 3A4 substrateNon-substrate0.5629
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5789
Ames testNon AMES toxic0.5451
CarcinogenicityNon-carcinogens0.6516
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0989 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9768
hERG inhibition (predictor II)Non-inhibitor0.8671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0019000000-fec3a7dbf1ba6b64f03e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0019000000-6a9b19701aa1af58166d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001l-0095000000-1aef30e1f36f3fcc9ea2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001j-0090000000-4f30705a14fab7bb25e0
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0090000000-8bf873219e6e4353be1e
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000y-0095000000-0a507959838acf3f73cb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0059000000-3ad0cecc4eb73cce225e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0069000000-be643d55172bd2292511
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001j-1290000000-33b23a68145a3ef2000c

Taxonomy

Description
This compound belongs to the class of organic compounds known as indenes and isoindenes. These are compounds containing an indene moiety(which consists of a cyclopentadiene fused to a benzene ring), or a isoindene moiety (which consists of a cyclopentadiene fused to cyclohexadiene ring).
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indenes and isoindenes
Sub Class
Not Available
Direct Parent
Indenes and isoindenes
Alternative Parents
Phenyl sulfoxides / Aryl fluorides / Sulfoxides / Sulfinyl compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organofluorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Phenyl sulfoxide / Indene / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Sulfoxide / Sulfinyl compound / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organofluorine compound, monocarboxylic acid, sulfoxide (CHEBI:9352)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30. [PubMed:10372826]
  2. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 Sep 1;59(17):4356-62. [PubMed:10485483]
  3. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000 Feb;21(2):139-46. [PubMed:10657949]
  4. Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000 Oct;37(5):431-502. [PubMed:11078056]
  5. Taylor MT, Lawson KR, Ignatenko NA, Marek SE, Stringer DE, Skovan BA, Gerner EW: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 2000 Dec 1;60(23):6607-10. [PubMed:11118042]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Giuliano F, Warner TD: Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol. 1999 Apr;126(8):1824-30. [PubMed:10372826]
  2. Lim JT, Piazza GA, Han EK, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol. 1999 Oct 1;58(7):1097-107. [PubMed:10484067]
  3. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999 Dec 15;59(24):6178-84. [PubMed:10626810]
  4. Cheng ZJ, Tikkanen I, Vapaatalo H, Mervaala EM: Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene. J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):597-613. [PubMed:12512695]
  5. Cheng ZJ, Finckenberg P, Louhelainen M, Merasto S, Tikkanen I, Vapaatalo H, Mervaala EM: Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur J Pharmacol. 2003 Feb 14;461(2-3):159-69. [PubMed:12586211]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glyceraldehyde oxidoreductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies.
Gene Name
AKR1B1
Uniprot ID
P15121
Uniprot Name
Aldose reductase
Molecular Weight
35853.125 Da
References
  1. Sharma YR, Vajpayee RB, Bhatnagar R, Mohan M, Azad RV, Kumar M, Nath R: Topical sulindac therapy in diabetic senile cataracts: cataract-IV. Indian J Ophthalmol. 1989 Jul-Sep;37(3):127-33. [PubMed:2632448]
  2. Crabbe MJ, Freeman G, Halder AB, Bron AJ: The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity. Ophthalmic Res. 1985;17(2):85-9. [PubMed:3920599]
  3. Chaudhry PS, Cabrera J, Juliani HR, Varma SD: Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8. [PubMed:6409111]
  4. Jacobson M, Sharma YR, Cotlier E, Hollander JD: Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1426-9. [PubMed:6413448]
  5. van der Sloot P, Mizisin A, Zochodne D: Sulindac in established experimental diabetes: a follow-up study. Can J Neurol Sci. 1995 Aug;22(3):198-201. [PubMed:8529171]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphatase binding
Specific Function
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK ca...
Gene Name
MAPK3
Uniprot ID
P27361
Uniprot Name
Mitogen-activated protein kinase 3
Molecular Weight
43135.16 Da
References
  1. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001 Feb 15;61(4):1541-7. [PubMed:11245463]
  2. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ: Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20. [PubMed:12566304]
  3. Rice PL, Beard KS, Driggers LJ, Ahnen DJ: Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res. 2004 Nov 15;64(22):8148-51. [PubMed:15548677]
  4. Pangburn HA, Kraus H, Ahnen DJ, Rice PL: Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J Carcinog. 2005 Sep 2;4:16. [PubMed:16138927]
  5. Rice PL, Peters SL, Beard KS, Ahnen DJ: Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther. 2006 Mar;5(3):746-54. [PubMed:16546990]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999 Oct 29;99(3):335-45. [PubMed:10555149]
  2. Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW: Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003 Nov 28;278(48):47762-75. Epub 2003 Sep 23. [PubMed:14506281]
  3. Jarvis MC, Gray TJ, Palmer CN: Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line. Oncogene. 2005 Dec 8;24(55):8211-5. [PubMed:16091736]
  4. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM: Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis. 2006 May;27(5):1105-12. Epub 2006 Jan 16. [PubMed:16418176]
  5. Liou JY, Ghelani D, Yeh S, Wu KK: Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007 Apr 1;67(7):3185-91. [PubMed:17409426]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinal dehydrogenase activity
Specific Function
Acts as all-trans-retinaldehyde reductase. Can efficiently reduce aliphatic and aromatic aldehydes, and is less active on hexoses (in vitro). May be responsible for detoxification of reactive aldeh...
Gene Name
AKR1B10
Uniprot ID
O60218
Uniprot Name
Aldo-keto reductase family 1 member B10
Molecular Weight
36019.295 Da
References
  1. Cousido-Siah A, Ruiz FX, Crespo I, Porte S, Mitschler A, Pares X, Podjarny A, Farres J: Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10. Chem Biol Interact. 2015 Jun 5;234:290-6. doi: 10.1016/j.cbi.2014.12.018. Epub 2014 Dec 20. [PubMed:25532697]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Russeva VN, Zhivkova ZD: Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin. Arzneimittelforschung. 2003;53(3):174-81. [PubMed:12705172]
  2. Shams-Eldeen MA, Vallner JJ, Needham TE: Interaction of sulindac and metabolite with human serum albumin. J Pharm Sci. 1978 Aug;67(8):1077-80. [PubMed:671241]
  3. Zhivkova ZD, Russeva VN: Thermodynamic characterization of the binding process of sulindac to human serum albumin. Arzneimittelforschung. 2003;53(1):53-6. [PubMed:12608015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:42